Drug Trial Radar · NCT06614907
A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Aug 31, 2024
Primary completion
Nov 15, 2024
Study completion Dec 27, 2024
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
It is a randomized, double-blinded, parallel, single-dose, PhaseⅠcomparative study to evaluate the pharmacokinetics and safety of QL2108 to Dupixent® in healthy Chinese adult subjects. A total of 198 healthy subjects are planned to be included and randomized at a ratio of 1:1 to receive single 300mg/2.0ml QL2108 injection or Dupixent®.
Conditions
- Atopic Dermatitis
Interventions
QL2108 injectionDrug
300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
Dupixent®Drug
300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics EndpointTime frame: 0-8weeks
- Pharmacokinetics EndpointTime frame: 0-8weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jinan Central Hospital
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.